Jason Bock trained in biology at MIT. Despite the appeal of burgeoning computer technology, he became captivated by the molecular nature of biology. Studying Molecular and Cellular Physiology at Stanford, his aim was to discover and clone new genes during the time when the genome was being sequenced. He later joined Human Genome Sciences (a 2012 GSK acquisition) to learn how to use these therapeutically. Over the following 20 years and more, his focus shifted to small, medium, and…
Read More…
Source: https://themedicinemaker.com/manufacture/new-platform-new-potential